Citations

Mayo Clinic

Showing 10 of 108551 citations.

Biomechanical Study Using Fresh Frozen Cadaveric Shoulders at the Mayo Clinic
Itoigawa, Yoshiaki , Kaneko, Kazuo, An, Kai‐Nan

Juntendo Medical Journal | January 13, 2016 | Volume: 61 | Issue: 5 | Pages: 479-483

10.14789/jmj.61.479 Get It

SGEF Is Regulated via TWEAK/Fn14/NF-κB Signaling and Promotes Survival by Modulation of the DNA Repair Response to Temozolomide
Ensign, Shannon P. Fortin , Roos, Alison , Mathews, Ian T. , Tuncali, Serdar, Symons, Marc , Loftus, Joseph C. , Tran, Nhan L. , Ensign, Shannon P. Fortin , Dhruv, Harshil , Sarkaria, Jann N. , Berens, Michael E. , Tran, Nhan L

Molecular Cancer Research | January 13, 2016 | Volume: 14 | Issue: 3 | Pages: 302-312

10.1158/1541-7786.mcr-15-0183 | PMID 26764186 Get It

Abstract Glioblastoma (GB) is the highest grade and most common form of primary adult brain tumors. Despite surgical removal followed by concomitant radiation and chemotherapy with the alkylating agent temozolomide, GB tumors develop treatment resistance and ultimately recur. Impaired response to treatment occurs rapidly, conferring a median survival of just fifteen months. Thus, it is necessary to identify the genetic and signaling mechanisms that promote tumor resistance to develop targeted therapies to combat this refractory disease. Previous observations indicated that SGEF (ARHGEF26), a RhoG-specific guanine nucleotide exchange factor (GEF), is overexpressed in GB tumors and plays a role in promoting TWEAK-Fn14–mediated glioma invasion. Here, further investigation revealed an important role for SGEF in glioma cell survival. SGEF expression is upregulated by TWEAK-Fn14 signaling via NF-κB activity while shRNA-mediated reduction of SGEF expression sensitizes glioma cells to temozolomide-induced apoptosis and suppresses colony formation following temozolomide treatment. Nuclear SGEF is activated following temozolomide exposure and complexes with the DNA damage repair (DDR) protein BRCA1. Moreover, BRCA1 phosphorylation in response to temozolomide treatment is hindered by SGEF knockdown. The role of SGEF in promoting chemotherapeutic resistance highlights a heretofore unappreciated driver, and suggests its candidacy for development of novel targeted therapeutics for temozolomide-refractory, invasive GB cells. Implication: SGEF, as a dual process modulator of cell survival and invasion, represents a novel target for treatment refractory glioblastoma. Mol Cancer Res; 14(3); 302–12. ©2016 AACR.
Commentary: Physician-Modified vs Off-the-Shelf Fenestrated and Branched Endografts
Oderich, Gustavo S.

Journal of Endovascular Therapy | January 13, 2016 | Volume: 23 | Issue: 1 | Pages: 110-114

10.1177/1526602815613520 | PMID 26763258 Get It

Transition of Care for Inpatient Hematology Patients Receiving Chemotherapy: Development of Hospital Discharge Huddle Process and Effects of Implementation
Warsame, Rahma , Kasi, Pashtoon Murtaza , Gallenberg, DeWayne, Matt-Hensrud, Natasha , Grethen, Kimberly, Colborn, Lisa K., Zeldenrust, Steven R., Lacy, Martha Q. , Thompson, Carrie A. , Kasi, Pashtoon M, Villasboas-Bisneto, Jose C, Wolf, Robert, Ward, James, Colborn, Lisa, Zeldenrust, Steven, Kasi, Pashtoon Murtaza , Villasboas, José C. , Wolf, Robert Christian , Ward, James

Journal of Oncology Practice | January 13, 2016 | Volume: 12 | Issue: 1 | Pages: e88-e94

10.1200/jop.2015.005785 | PMID 26374861 Get It

Developing a systematic approach to hospital discharges can lead to improvements and serve a model for other inpatient wards.
Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women
Zeitler, Emily P. , Hellkamp, Anne S., Schulte, Phillip J. , Fonarow, Gregg C. , Sanders, Gillian D, Hernandez, Adrian F. , Yancy, Clyde W. , Al-Khatib, Sana M, Peterson, Eric D. , Al‐Khatib, Sana M.

Circulation: Heart Failure | January 13, 2016 | Volume: 9 | Issue: 1 | Pages: No page available

10.1161/circheartfailure.115.002630 | PMID 26758365 Get It

Background— Clinical trials of implantable cardioverter defibrillators (ICDs) for primary prevention enrolled a limited number of women. We sought to examine clinical practice data to compare survival rates among women with heart failure with or without a primary prevention ICD. Methods and Results— We linked data from 264 US hospitals included in the Get With The Guidelines for Heart Failure registry with data from the Centers for Medicare and Medicaid Services. From these sources, we propensity score matched 430 women with heart failure who received a primary prevention ICD to 430 women who did not; we further adjusted using a Cox proportional hazards model. Median follow-up was 3.4 and 3.0 years. For comparison, we matched 859 men receiving an ICD with 859 who did not; median follow-up was 3.9 versus 2.9 years. In the matched cohorts, an ICD was associated with similarly better survival in women (hazard ratio, 0.78; 95% confidence interval, 0.66–0.92; P =0.003) and men (hazard ratio, 0.76; 95% confidence interval, 0.67–0.87 P <0.001). There was no interaction between sex and presence of an ICD with respect to survival ( P =0.79). Conclusions— Among patients with heart failure with reduced left ventricular ejection fraction, a primary prevention ICD was associated with a significant survival advantage among women and among men. These findings support guideline-directed use of primary prevention ICDs in eligible patients.
Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care?
Mair, Johannes , Giannitsis, Evangelos , Huber, Kurt , Thygesen, Kristian , Möckel, Martin , Jaffe, Allan S. , Lindahl, Bertil , Giannitsis, Evangelos , Plebani, Mario , Müller, Christian , Jaffe, Allan S. , Huber, Kurt , Mockel, Martin

European Heart Journal: Acute Cardiovascular Care | January 13, 2016 | Volume: 6 | Issue: 4 | Pages: 321-328

10.1177/2048872615626355 | PMID 26758541 Get It

SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio‐oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiolog
Iliescu, Cezar , Herrmann, Joerg , Yang, Eric H. , Charitakis, Konstantinos, Hakeem, Abdul , Tοutouzas, Konstantinos, Leesar, Massoud A. , Marmagkiolis, Konstantinos , Grines, Cindy L. , Çilingiroğlu, Mehmet , Yang, Eric

Catheterization and Cardiovascular Interventions | January 13, 2016 | Volume: 87 | Issue: 5 | Pages: No page available

10.1002/ccd.26379 | PMID 26756277 Get It

In the United States alone, there are currently approximately 14.5 million cancer survivors, and this number is expected to increase to 20 million by 2020. Cancer therapies can cause significant injury to the vasculature, resulting in angina, acute coronary syndromes (ACS), stroke, critical limb ischemia, arrhythmias, and heart failure, independently from the direct myocardial or pericardial damage from the malignancy itself. Consequently, the need for invasive evaluation and management in the cardiac catheterization laboratory (CCL) for such patients has been increasing. In recognition of the need for a document on special considerations for cancer patients in the CCL, the Society for Cardiovascular Angiography and Interventions (SCAI) commissioned a consensus group to provide recommendations based on the published medical literature and on the expertise of operators with accumulated experience in the cardiac catheterization of cancer patients. © 2016 Wiley Periodicals, Inc.
Model-Based Quantification of Glucagon-Like Peptide-1–Induced Potentiation of Insulin Secretion in Response to a Mixed Meal Challenge
Man, Chiara Dalla , Micheletto, Francesco, Sathananthan, Matheni, Vella, Adrian , Cobelli, Claudio , Dalla Man, Chiara

Diabetes Technology & Therapeutics | January 12, 2016 | Volume: 18 | Issue: 1 | Pages: 39-46

10.1089/dia.2015.0146 | PMID 26756104 Get It

Background: Glucagon-like peptide-1 (GLP-1) is a powerful insulin secretagogue that is secreted in response to meal ingestion. The ability to quantify the effect of GLP-1 on insulin secretion could provide insights into the pathogenesis and treatment of diabetes. We used a modification of a model of GLP-1 action on insulin secretion using data from a hyperglycemic clamp with concomitant GLP-1 infusion. We tested this model using data from a mixed meal test (MMT), thereby measuring GLP-1-induced potentiation of insulin secretion in response to a meal. Materials and Methods: The GLP-1 model is based on the oral C-peptide minimal model and assumes that over-basal insulin secretion depends linearly on GLP-1 concentration through the parameter Π, representing the β-cell sensitivity to GLP-1. The model was tested on 62 subjects across the spectrum of glucose tolerance (age, 53 ± 1 years; body mass index, 29.7 ± 0.6 kg/m 2 ) studied with an MMT and provided a precise estimate of both β-cell responsivity and Π indices. By combining Π with a measure of L-cell responsivity to glucose, one obtains a potentiation index (PI) (i.e., a measure of the L-cell's function in relation to prevailing β-cell sensitivity to GLP-1). Results: Model-based measurement of GLP-1-induced insulin secretion demonstrates that the PI is significantly reduced in people with impaired glucose tolerance, compared with those with normal glucose tolerance. Conclusions: We describe a model that can quantitate the GLP-1-based contribution to insulin secretion in response to meal ingestion. This methodology will allow a better understanding of β-cell function at various stages of glucose tolerance.
How Can We Improve the Quality of Life of Dialysis Patients?
Mitema, Donald, Jaar, Bernard G.

Seminars in Dialysis | January 12, 2016 | Volume: 29 | Issue: 2 | Pages: 93-102

10.1111/sdi.12467 | PMID 26757059 Get It

AbstractAs medical advances are made in the care of persons with chronic illnesses including those with end‐stage renal disease (ESRD), patients are not only experiencing increasing life expectancy but also bearing the burden of illness and treatment for a longer duration of time. With this in mind, it is increasingly important for health care providers to pay close attention to their individual patient's perceptions of their health, fitness, life satisfaction, and well‐being. This assessment of Health‐Related Quality of Life (HRQOL) also includes an evaluation of the patient's level of satisfaction with treatment, outcome, and health status, also taking into account their perspective on future prospects. In addition to improving patient–provider communication by helping in the identification and prioritization of problems, it is important to note that high HRQOL has been shown to be associated with better medical outcomes, including reduction in hospitalizations and death. In this review, we outline several validated tools that are used to quantitatively measure HRQOL in the ESRD population and incorporate these instruments in a review of specific, evidence‐based measures by which we can measurably improve health‐related quality of life in dialysis patients.
A Cross-Sectional Analysis of Late-Life Cardiovascular Factors and Their Relation to Clinically Defined Neurodegenerative Diseases
Dugger, Brittany N. , Malek‐Ahmadi, Michael , Monsell, Sarah E. , Kukull, Walter A. , Woodruff, Bryan K. , Reiman, Eric M. , Beach, Thomas G. , Wilson, Jeffrey R. , Dugger, Brittany N

Alzheimer Disease & Associated Disorders | January 12, 2016 | Volume: 30 | Issue: 3 | Pages: 223-229

10.1097/wad.0000000000000138 | PMID 26756386 Get It

Studies have demonstrated associations between cardiovascular factors and Alzheimer disease (AD) with minimal focus on other neurodegenerative diseases. Utilizing cross-sectional data from 17,532 individuals in the National Alzheimer’s Coordinating Center, Uniform Data Set, we compared the presence of cardiovascular factors [body mass index (BMI), atrial fibrillation, hypertension, hyperlipidemia, and diabetes] in individuals carrying a diagnosis of Probable AD (ProbAD), Possible AD, vascular dementia, dementia with Lewy bodies (DLB), frontotemporal dementia, Parkinson disease, progressive supranuclear palsy, or corticobasal degeneration, with that of normals. Generalized linear mixed models were fitted with age at visit, gender, and cardiovascular factors as fixed effects and Alzheimer’s Disease Centers as random effects. In late life, only BMI of ProbAD and DLB patients was statistically significantly lower than that in normals (P–values <0.001). When accounting for colinearity within cardiovascular factors, a low BMI was a comorbidity of certain dementia etiologies as compared with normals. These data support a concept of disease-specific associations with certain cardiovascular factors.